Enanta Pharmaceuticals (NASDAQ:ENTA) Insider Sells $34,009.70 in Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) insider Yat Sun Or sold 2,390 shares of the stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $34,009.70. Following the sale, the insider owned 371,392 shares in the company, valued at $5,284,908.16. The trade was a 0.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Enanta Pharmaceuticals Trading Up 3.6%

Shares of ENTA stock traded up $0.51 during trading hours on Friday, reaching $14.60. 333,749 shares of the stock were exchanged, compared to its average volume of 400,542. The company’s 50-day moving average price is $11.89 and its 200-day moving average price is $9.04. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.09 and a 12-month high of $15.34. The firm has a market capitalization of $421.36 million, a price-to-earnings ratio of -3.81 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 17th. The biotechnology company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. The business had revenue of $15.13 million during the quarter, compared to analyst estimates of $15.60 million. On average, sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Wall Street Analyst Weigh In

ENTA has been the topic of several analyst reports. JPMorgan Chase & Co. began coverage on shares of Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 price target on the stock. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the company from $14.00 to $20.00 in a report on Wednesday, October 1st. JMP Securities boosted their target price on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 12th. Westpark Capital boosted their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. Finally, Evercore ISI decreased their target price on Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday, September 15th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $20.33.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC increased its stake in Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after purchasing an additional 449,945 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Enanta Pharmaceuticals by 2.1% in the first quarter. Acadian Asset Management LLC now owns 867,037 shares of the biotechnology company’s stock valued at $4,782,000 after purchasing an additional 17,613 shares in the last quarter. Marshall Wace LLP increased its stake in Enanta Pharmaceuticals by 0.8% during the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after buying an additional 6,522 shares during the period. Commodore Capital LP purchased a new position in Enanta Pharmaceuticals in the 3rd quarter valued at approximately $9,576,000. Finally, Stonepine Capital Management LLC increased its position in shares of Enanta Pharmaceuticals by 2.3% during the second quarter. Stonepine Capital Management LLC now owns 604,066 shares of the biotechnology company’s stock worth $4,567,000 after acquiring an additional 13,324 shares during the period. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.